Core Insights - International Isotopes Inc. reported a revenue increase of 15.3% for Q2 2025 and 13.5% for the first half of 2025 compared to the previous year, driven by sales growth in Nuclear Medicine Standards and Cobalt products [1][2][3] - The company improved its net loss for Q2 2025 to $160,785, a 27% improvement from the previous year, and for the first half of 2025 to $273,479, a 29.4% improvement [1][8] - Non-GAAP EBITDA for Q2 2025 was $1,199, a significant increase from a loss of $84,021 in the same period last year, while the first half of 2025 saw a 157% improvement to $51,569 [1][13] Revenue Breakdown - Revenue from Theranostics Products decreased by 9% to $3,692,233 for the first half of 2025, primarily due to the loss of standing order customers [3] - Revenue from Nuclear Medicine Standards products surged by 99% to $2,340,580 for the first half of 2025, attributed to the resolution of a global shortage of Cobalt-57 isotope [4] - Revenue from Cobalt Products fell by 9% to $750,465 for the first half of 2025, influenced by the timing of sales [5] - Medical Devices segment generated $58,089 in revenue for the first half of 2025, marking its first sales since being established as a reportable segment [6] Financial Performance - Gross profit for Q2 2025 was $2,141,559, a 6.1% increase from the previous year, while total operating expenses rose by 3.6% [7] - The operating loss before other income improved by 25.1% for Q2 2025 compared to the previous year [7] - Adjusted EBITDA for the first half of 2025 was $174,020, a decrease of 51% compared to the previous year [13]
INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025